People: Pain Therapeutics Inc (PTIE.O)

PTIE.O on Nasdaq

2.06USD
19 Dec 2014
Price Change (% chg)

$0.03 (+1.48%)
Prev Close
$2.03
Open
$2.00
Day's High
$2.09
Day's Low
$1.96
Volume
273,705
Avg. Vol
384,036
52-wk High
$6.22
52-wk Low
$1.61

Search Stocks

Summary

Name Age Since Current Position

Remi Barbier

54 1998 Chairman of the Board, President, Chief Executive Officer

Peter Roddy

54 2004 Chief Financial Officer, Vice President

Nadav Friedmann

71 2004 Chief Medical and Operating Officer, Director

Michael O' Donnell

55 Secretary, Independent Director

Robert Gussin

76 2003 Independent Director

Saira Ramasastry

38 2013 Independent Director

Sanford Robertson

82 1998 Independent Director

Patrick Scannon

66 2007 Independent Director

Biographies

Name Description

Remi Barbier

Mr. Remi Barbier is Chairman of the Board, President, Chief Executive Officer of Pain Therapeutics, Inc., since May 1998. Prior to that time, Mr. Barbier helped in the growth or founding of: Exelixis Inc., a functional genomics company, ArQule, Inc., a chemistry company, and EnzyMed, Inc. (now owned by Albany Molecular Research, Inc.), a chemistry company. Mr. Barbier served as Chief Operating Officer of Exelixis, Inc. from January 1996 to May 1998. Mr. Barbier was Vice President of Corporate Development and Clinical Project Manager of Xoma Corporation, a biotechnology company, from 1993 to 1995. Mr. Barbier is a trustee of the Carnegie Institute of Washington and is on the Advisory Board of the California Institute for Quantitative Biosciences. Mr. Barbier received his B.A. from Oberlin College and his M.B.A. from the University of Chicago.

Peter Roddy

Mr. Peter S. Roddy is Chief Financial Officer, Vice President of Pain Therapeutics, Inc. He has served as Chief Financial Officer since 2002 and as Vice President and Chief Financial Officer since 2004. From 1990 to 2002, Mr. Roddy held a variety of senior management positions at COR Therapeutics, Inc., a biopharmaceutical company, including Senior Vice President, Finance and Chief Financial Officer between 2000 and 2002. Prior to 1990, Mr. Roddy held a variety of positions at Price Waterhouse & Company, Hewlett Packard Company and MCM Laboratories, Inc. Mr. Roddy is a director of Vermillion, Inc., a publicly-held medical diagnostics company. Mr. Roddy received his B.S. in Business Administration from the University of California, Berkeley.

Nadav Friedmann

Dr. Nadav Friedmann, M.D., Ph.D., is Chief Medical and Operating Officer, Director of Pain Therapeutics, Inc. He has served as a director since 1998. Dr. Friedmann has served as Chief Operating Officer since October 2001 and Chief Medical and Operating Officer since 2004. Dr. Friedmann is the owner and President of EMET Research Inc., a consulting firm in the pharmaceutical industry. Dr. Friedmann was President and Chief Executive Officer of Daiichi Pharmaceutical Corporation, a pharmaceutical company, from 1997 to 2000, and was a consultant to the Board of Directors of Daiichi Pharmaceutical Co., Ltd. in Tokyo from 1995 to 1997. From 1992 to 1995, Dr. Friedmann served as Vice President, Clinical Research at Xoma Ltd. (formerly Xoma Corporation). From 1980 to 1991, Dr. Friedmann held various leadership positions with Johnson & Johnson (“J&J”), including the position of Vice President and Head of Research of the J&J Biotechnology Center. Prior to that, Dr. Friedmann was Medical Director of Abbott Laboratories. Dr. Friedmann received his M.D. from the Albert Einstein College of Medicine and his Ph.D. in Biochemistry from the University of California, San Diego.

Michael O' Donnell

Mr. Michael J. O' Donnell, Esq., is Secretary, Independent Director of Pain Therapeutics Inc. Mr. O’Donnell has been a member of the law firm of Morrison & Foerster, LLP since January 2011. From 1993 to January 2011, Mr. O’Donnell was a member of the law firm of Wilson Sonsini Goodrich & Rosati, Professional Corporation. Morrison & Foerster, LLP is the Company’s corporate counsel and provides legal services to the Company. Mr. O’Donnell serves as corporate counsel to numerous public and private biopharmaceutical and life sciences companies. Mr. O’Donnell received his J.D., cum laude, from Harvard University and his B.A. from Bucknell University, summa cum laude.

Robert Gussin

Dr. Robert Z. Gussin, Ph.D., is an Independent Director of Pain Therapeutics Inc., since March 2003. Dr. Gussin worked at J&J for 26 years, most recently as Chief Scientific Officer and Corporate Vice President, Science and Technology from 1986 through his retirement in 2000. Prior to assuming this role, Dr. Gussin worked at J&J’s McNeil division for 12 years, most recently as Vice President, Research and Development and Vice President, Scientific Affairs. From 1967 to 1974, Dr. Gussin held various research positions with Lederle Laboratories, a pharmaceutical company. Dr. Gussin sits on the Board of Directors of Duquesne University and the advisory boards of the Duquesne University Pharmacy School and the University of Michigan Medical School Department of Pharmacology. Dr. Gussin received his B.S. and M.S. degrees and D.Sc. with honors from Duquesne University and his Ph.D. in Pharmacology from the University of Michigan, Ann Arbor.

Saira Ramasastry

Ms. Saira Ramasastry is an Independent Director of Pain Therapeutics, Inc. Prior to 2013, Ms. Ramasastry was an advisor to the Company. Since 2009 she has served as Managing Partner of Life Sciences Advisory, LLC, a life science company advisory business. From 1999 to 2009, Ms. Ramasastry was an investment banker with Merrill Lynch & Company, Inc., an investment banking firm. From 1997 to 1998, she was a financial analyst in the M&A group at Wasserstein Perella & Co., an investment banking firm. Ms. Ramasastry serves on the Board of Directors of Sangamo Biosciences, Inc. and Repros Therapeutics, Inc., each a publicly-held biopharmaceutical company, the Industry Advisory Board of the Michael J. Fox Foundation for Parkinson’s Research and the Board of Directors of the American Liver Foundation. She received a B.A. in Economics with Honors and Distinction and an M.S. in Management Science and Engineering from Stanford University, Phi Beta Kappa, as well as an M. Phil. in Management Studies from the University of Cambridge.

Sanford Robertson

Mr. Sanford R. Robertson is an Independent Director of Pain Therapeutics Inc., since 1998. Mr. Robertson has been a partner of Francisco Partners, a technology buyout fund, since 1999. Prior to founding Francisco Partners, Mr. Robertson was the founder and chairman of Robertson, Stephens & Company, a technology investment bank formed in 1978 and sold to BankBoston in 1998. Since the sale, Mr. Robertson has been a technology investor and advisor to several technology companies. Mr. Robertson was also the founder of Robertson, Colman, Siebel & Weisel, later renamed Montgomery Securities, another technology investment bank. Mr. Robertson is a director of Salesforce.com, a publicly-held provider of enterprise cloud computing applications, Dolby Laboratories, Inc., a publicly-held entertainment technology company and RPX, Inc., a publicly-held provider of patent risk solutions. Mr. Robertson received his B.A. and M.B.A. degrees with distinction from the University of Michigan.

Patrick Scannon

Dr. Patrick J. Scannon, M.D., Ph.D., is an Independent Director of Pain Therapeutics Inc., since 2007. Dr. Scannon is a director of and one of the founders of XOMA, Ltd. Dr. Scannon has been Executive Vice President, Chief Biotechnology Officer of XOMA Ltd. since 2006. From 1993 to 2006, Dr. Scannon served as Chief Scientific and Medical Officer of XOMA, Ltd. Dr. Scannon received his Ph.D. in organic chemistry from the University of California, Berkeley and his M.D. from the Medical College of Georgia.

Basic Compensation

Name Fiscal Year Total

Remi Barbier

1,988,640

Peter Roddy

596,147

Nadav Friedmann

865,167

Michael O' Donnell

--

Robert Gussin

--

Saira Ramasastry

--

Sanford Robertson

--

Patrick Scannon

--
As Of 30 Dec 2013

Options Compensation

Name Options Value

Remi Barbier

1,453,468 458,019

Peter Roddy

515,000 978,350

Nadav Friedmann

1,221,790 877,335

Michael O' Donnell

0 0

Robert Gussin

0 0

Saira Ramasastry

0 0

Sanford Robertson

0 0

Patrick Scannon

0 0
Search Stocks